trending Market Intelligence /marketintelligence/en/news-insights/trending/aI5wvsceStRI3HgsgjfKJQ2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Matinas to raise $50M from common stock offering

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

Matinas to raise $50M from common stock offering

Matinas BioPharma Holdings Inc. priced a public offering of its common stock to raise $50 million in gross proceeds.

The Bedminster, N.J.-based biopharmaceutical company is offering 32,260,000 shares at $1.55 apiece. Underwriters will also receive an option to buy up to an additional 4,839,000 shares.

The offering is scheduled to close Jan. 14.

Matinas intends to use the net proceeds from the offering to continue developing its drug candidates — with a main focus on MAT9001 for treating heart and metabolic conditions — and for general corporate purposes.

Piper Sandler & Co. is acting as the sole lead active bookrunner for the offering, with SunTrust Robinson Humphrey also acting as a book runner. BTIG LLC is acting as lead manager and H.C. Wainwright & Co., Maxim Group LLC and Roth Capital Partners are acting as co-managers.